Morillas 2000 Biochem J: Difference between revisions
(Created page with "{{Publication |title=Morillas M,Clotet J, Rubí B, Serra D, Ariño J, Hegardt FG, Asins G (2000) Inhibition by etomoxir of rat liver carnitine octanoyltransferase is produced...") |
No edit summary |
||
| Line 1: | Line 1: | ||
{{Publication | {{Publication | ||
|title=Morillas M,Clotet J, Rubí B, Serra D, Ariño J, Hegardt FG, Asins G (2000) Inhibition by etomoxir of rat liver carnitine octanoyltransferase is produced through the co-ordinate interaction with two histidine residues. Biochem J 351:495-502 | |title=Morillas M, Clotet J, Rubí B, Serra D, Ariño J, Hegardt FG, Asins G (2000) Inhibition by etomoxir of rat liver carnitine octanoyltransferase is produced through the co-ordinate interaction with two histidine residues. Biochem J 351:495-502. | ||
|info=[https://pubmed.ncbi.nlm.nih.gov/11023836/ PMID:11023836/ Open Access] | |info=[https://pubmed.ncbi.nlm.nih.gov/11023836/ PMID:11023836/ Open Access] | ||
|authors=Morillas M,Clotet J, Rubí B, Serra D, Ariño J, Hegardt FG, Asins G | |authors=Morillas M,Clotet J, Rubí B, Serra D, Ariño J, Hegardt FG, Asins G | ||
| Line 7: | Line 7: | ||
|abstract=Rat peroxisomal carnitine octanoyltransferase (COT), which facilitates the transport of medium-chain fatty acids through the peroxisomal membrane, is irreversibly inhibited by the hypoglycaemia-inducing drug etomoxir. To identify the molecular basis of this inhibition, cDNAs encoding full-length wild-type COT, two different variant point mutants and one variant double mutant from rat peroxisomal COT were expressed in Saccharomyces cerevisiae, an organism devoid of endogenous COT activity. The recombinant mutated enzymes showed activity towards both carnitine and decanoyl-CoA in the same range as the wild type. Whereas the wild-type version expressed in yeast was inhibited by etomoxir in an identical manner to COT from rat liver peroxisomes, the activity of the enzyme containing the double mutation H131A/H340A was completely insensitive to etomoxir. Individual point mutations H131A and H340A also drastically reduced sensitivity to etomoxir. Taken together, these results indicate that the two histidine residues, H131 and H340, are the sites responsible for inhibition by etomoxir and that the full inhibitory properties of the drug will be shown only if both histidines are intact at the same time. Our data demonstrate that both etomoxir and malonyl-CoA inhibit COT by interacting with the same sites. | |abstract=Rat peroxisomal carnitine octanoyltransferase (COT), which facilitates the transport of medium-chain fatty acids through the peroxisomal membrane, is irreversibly inhibited by the hypoglycaemia-inducing drug etomoxir. To identify the molecular basis of this inhibition, cDNAs encoding full-length wild-type COT, two different variant point mutants and one variant double mutant from rat peroxisomal COT were expressed in Saccharomyces cerevisiae, an organism devoid of endogenous COT activity. The recombinant mutated enzymes showed activity towards both carnitine and decanoyl-CoA in the same range as the wild type. Whereas the wild-type version expressed in yeast was inhibited by etomoxir in an identical manner to COT from rat liver peroxisomes, the activity of the enzyme containing the double mutation H131A/H340A was completely insensitive to etomoxir. Individual point mutations H131A and H340A also drastically reduced sensitivity to etomoxir. Taken together, these results indicate that the two histidine residues, H131 and H340, are the sites responsible for inhibition by etomoxir and that the full inhibitory properties of the drug will be shown only if both histidines are intact at the same time. Our data demonstrate that both etomoxir and malonyl-CoA inhibit COT by interacting with the same sites. | ||
}} | }} | ||
== Cited by == | |||
{{Template:Cited by Silva 2021 MitoFit Etomoxir}} | |||
{{Labeling | {{Labeling | ||
|additional=MitoFit 2021 Etomoxir | |additional=MitoFit 2021 Etomoxir | ||
}} | }} | ||
Latest revision as of 10:13, 6 July 2021
| Morillas M, Clotet J, Rubí B, Serra D, Ariño J, Hegardt FG, Asins G (2000) Inhibition by etomoxir of rat liver carnitine octanoyltransferase is produced through the co-ordinate interaction with two histidine residues. Biochem J 351:495-502. |
Morillas M, Clotet J, Rubí B, Serra D, Ariño J, Hegardt FG, Asins G (2000) Biochem J
Abstract: Rat peroxisomal carnitine octanoyltransferase (COT), which facilitates the transport of medium-chain fatty acids through the peroxisomal membrane, is irreversibly inhibited by the hypoglycaemia-inducing drug etomoxir. To identify the molecular basis of this inhibition, cDNAs encoding full-length wild-type COT, two different variant point mutants and one variant double mutant from rat peroxisomal COT were expressed in Saccharomyces cerevisiae, an organism devoid of endogenous COT activity. The recombinant mutated enzymes showed activity towards both carnitine and decanoyl-CoA in the same range as the wild type. Whereas the wild-type version expressed in yeast was inhibited by etomoxir in an identical manner to COT from rat liver peroxisomes, the activity of the enzyme containing the double mutation H131A/H340A was completely insensitive to etomoxir. Individual point mutations H131A and H340A also drastically reduced sensitivity to etomoxir. Taken together, these results indicate that the two histidine residues, H131 and H340, are the sites responsible for inhibition by etomoxir and that the full inhibitory properties of the drug will be shown only if both histidines are intact at the same time. Our data demonstrate that both etomoxir and malonyl-CoA inhibit COT by interacting with the same sites.
Cited by
- Silva et al (2021) Off-target effect of etomoxir on mitochondrial Complex I. MitoFit Preprints 2021. (in preparation)
Labels:
MitoFit 2021 Etomoxir
